- Bruker Corp‘s fourth-quarter revenue reached $979.6 million, surpassing the estimate of $966.2 million.
- The company’s adjusted earnings per share (EPS) for the fourth quarter were 76 cents, beating the estimated 74 cents.
- For fiscal year 2025, Bruker projects non-GAAP EPS to be between $2.67 and $2.72.
- This represents an increase of 11% to 13% from the fiscal year 2024 non-GAAP EPS of $2.41.
- Bruker’s constant exchange rate (CER) non-GAAP EPS growth is expected to be between 14% and 16%.
- Analyst recommendations for Bruker include 8 buy ratings, 6 hold ratings, and 1 sell rating.
A look at Bruker Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, the long-term outlook for Bruker Corp seems moderately positive. While the company scores average marks in areas such as Value and Dividend, it stands out more in terms of Growth and Momentum, scoring a 3 in both. This suggests a potential for future expansion and market performance based on these factors.
Bruker Corp is a company that designs and manufactures life science systems using spectrometry technology platforms. Additionally, they offer field analytical systems for substance detection and pathogen identification, as well as research tools based on X-ray technology. With a mix of moderate scores across different areas, Bruker Corp appears positioned for steady growth and resilience in the market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
